Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Clearside biomedical, inc. save search
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $118.31 -3.71% -3.79% 860K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2023-11-03 (Crawled : 23:00) - prnewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 altitude year one positive treatment trial diabetic
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: -3.44%
H: 6.1%
C: 3.66%
xipere macular treatment trial china
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
Published: 2023-07-10 (Crawled : 11:00) - globenewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.0%
H: 3.71%
C: -0.93%
arcatus drug australia macular treatment application
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
|
| O: -3.01%
H: 0.77%
C: -10.46%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.74%
H: 11.76%
C: 7.35%
rgx-314 altitude treatment expansion trial positive diabetic
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Published: 2022-10-03 (Crawled : 13:00) - biospace.com/
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
|
| O: 2.16%
H: 0.3%
C: -10.48%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.88%
H: 5.26%
C: 5.26%
rgx-314 treatment trials positive
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2022-03-28 (Crawled : 19:00) - biospace.com/
BHC | $8.63 -1.48% -1.51% 3M
|
Health Technology
|
| O: -0.35%
H: 0.09%
C: -0.7%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 2.97%
H: 2.47%
C: -3.7%
xipere treatment macular
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-02-12 (Crawled : 20:20) - prnewswire.com
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
| Email alert
Add to watchlist
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 treatment liver trial positive diabetic diabetes
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: -1.03%
H: 4.18%
C: 0.7%
treatment axitinib trial cls-ax phase 1 positive results
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME)
Published: 2021-11-22 (Crawled : 19:00) - biospace.com/
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.0%
H: 0.69%
C: -10.98%
arvn001 treatment ema macular arvn004
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2021-10-25 (Crawled : 11:00) - biospace.com/
BHC | $8.63 -1.48% -1.51% 3M
|
Health Technology
|
| O: 0.28%
H: 1.95%
C: 0.9%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 3.49%
H: 8.51%
C: -0.89%
treatment fda ema fda approval approval macular xipere injection
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
Published: 2021-10-09 (Crawled : 16:20) - prnewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
| Email alert
Add to watchlist
treatment positive retina liver trial diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
RGNX | $18.02 -0.39% -0.28% 350K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: -1.5%
H: 0.0%
C: 0.0%
treatment positive retina liver trial
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 32.42%
H: 20.02%
C: 4.03%
treatment phase 1 positive results trial phase 3 phase 2 axitinib cls-ax dmd injection
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
BHC | $8.63 -1.48% -1.51% 3M
|
Health Technology
|
| O: 0.09%
H: 0.68%
C: -2.42%
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 1.63%
H: 1.28%
C: -4.49%
new drug treatment drug macular submission xipere application resubmission
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-03-02 (Crawled : 13:01) - globenewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 3.48%
H: 0.28%
C: -4.48%
treatment phase 1 trial phase 3 phase 2 axitinib cls-ax dmd injection
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-01-12 (Crawled : 13:00) - globenewswire.com
CLSD | $1.29 3.2% 2.34% 180K
|
Health Technology
|
| O: 0.54%
H: 1.36%
C: -2.44%
trial phase 3 phase 1 phase 2 treatment axitinib cls-ax dmd injection enroll
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.